☆ 4.6 Review

Sarcomere protein modulation: The new frontier in cardiovascular medicine and beyond

EUROPEAN JOURNAL OF INTERNAL MEDICINE (2022)

Related references

Note: Only part of the references are listed.

Article Cardiac & Cardiovascular Systems

Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure A Post Hoc Analysis of Data From the GALACTIC-HF Randomized Clinical Trial

G. Michael Felker et al.

Summary: This study evaluated the efficacy and safety of omecamtiv mecarbil for severe heart failure patients. The results suggest that omecamtiv mecarbil therapy may have clinically meaningful benefits for patients with severe heart failure, supporting its potential role in patients with limited treatment options.

JAMA CARDIOLOGY (2022)

Add to Collection

Article Clinical Neurology

A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial OfReldesemtivIn Patients With ALS

Jeremy M. Shefner et al.

Summary: This study evaluated the safety, dose response, and preliminary efficacy of reldesemtiv in patients with ALS. Although the primary efficacy analysis did not demonstrate statistical significance, post hoc analyses showed trends favoring reldesemtiv in all endpoints, with good tolerability.

AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Pathophysiology and Treatment of Hypertrophic Cardiomyopathy: New Perspectives

Mattia Zampieri et al.

Summary: This review discusses the latest developments in therapeutic options for hypertrophic cardiomyopathy (HCM), focusing on our evolving understanding of the disease's pathophysiology and newly developed drug treatments. Recent research in the molecular mechanisms associated with HCM has opened up new possibilities for targeting the disease at a genetic level. Novel evidence-based approaches offer hope for altering the natural history of HCM through targeted interventions in the near future.

CURRENT HEART FAILURE REPORTS (2021)

Add to Collection

Article Medicine, General & Internal

Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure

John R. Teerlink et al.

Summary: Among patients with heart failure and reduced ejection fraction, those who received omecamtiv mecarbil had a lower incidence of heart-failure events or cardiovascular death compared to those who received placebo over a median of 22 months.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Chemistry, Medicinal

Discovery of Aficamten (CK-274), a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy

Chihyuan Chuang et al.

Summary: Aficamten is a novel cardiac myosin inhibitor designed to have predicted human half-life and steady state concentration, with potential clinical applications due to its optimized structure-activity relationship. In a phase I clinical trial, it demonstrated similar human half-life to predictions and achieved steady state concentration within the desired time frame.

JOURNAL OF MEDICINAL CHEMISTRY (2021)

Add to Collection

Article Chemistry, Medicinal

Discovery of Reldesemtiv, a Fast Skeletal Muscle Troponin Activator for the Treatment of Impaired Muscle Function

Scott E. Collibee et al.

Summary: The discovery of reldesemtiv, a second-generation fast skeletal muscle troponin activator (FSTA), has shown improved muscle force generation in comparison to the first-generation FSTA tirasemtiv, making it a promising candidate for the treatment of amyotrophic lateral sclerosis.

JOURNAL OF MEDICINAL CHEMISTRY (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy

Sheila M. Hegde et al.

Summary: The BACKGROUND EXPLORER-HCM study showed that mavacamten can significantly improve left ventricular diastolic function and systolic anterior motion in patients with obstructive hypertrophic cardiomyopathy. Improvement in LVOT obstruction, LAVI, and E/e' was associated with reduction in a biomarker of myocardial wall stress.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)

Add to Collection

Review Biology

Cardiac myosin super relaxation (SRX): a perspective on fundamental biology, human disease and therapeutics

Manuel Schmid et al.

Summary: This article discusses the discovery of the super relaxed state of myosin and its role in regulating muscle contraction, explores the prospect of therapeutic development for cardiovascular disease and infectious disease through modulation of myosin function, and the potential application for treating hypertrophic cardiomyopathy.

BIOLOGY OPEN (2021)

Add to Collection

Review Medicine, General & Internal

Emerging Medical Treatment for Hypertrophic Cardiomyopathy

Alessia Argiro et al.

Summary: Hypertrophic cardiomyopathy (HCM) is a common myocardial disease characterized by unexplained left ventricular hypertrophy. LVOT obstruction is the main cause of disabling symptoms in patients with HCM, with treatments focusing on attenuating myocardial hypercontractility. The review discusses current treatment modalities and emerging therapeutic opportunities, including new drugs such as Mavacamten and CK-274.

JOURNAL OF CLINICAL MEDICINE (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Molecular Genetic Basis of Hypertrophic Cardiomyopathy

A. J. Marian

Summary: Hypertrophic cardiomyopathy (HCM) is a genetic disease characterized by left ventricular hypertrophy and may lead to heart failure or sudden cardiac death. Pathogenic variants in genes encoding myocardial protein constituents, especially MYH7 and MYBPC3 genes, are the main causes of HCM. Advances in genetic testing and drug development have improved the therapeutic prospects for HCM.

CIRCULATION RESEARCH (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

LONG-TERM SAFETY OF MAVACAMTEN IN PATIENTS WITH OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY: INTERIM RESULTS OF THE MAVA-LONG TERM EXTENSION (LTE) STUDY

Florian Rader et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

Theresa A. McDonagh et al.

EUROPEAN HEART JOURNAL (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial

Carolyn Y. Ho et al.

Summary: In a randomized phase 2 clinical trial, the angiotensin receptor blocker valsartan showed promising results in improving cardiac structure and function in patients with early-stage hypertrophic cardiomyopathy, suggesting a potential safe and accessible treatment option to attenuate disease progression.

NATURE MEDICINE (2021)

Add to Collection

Article Biophysics

Characterization of the Cardiac Myosin Inhibitor CK-3773274: a Potential Therapeutic Approach for Hypertrophic Cardiomyopathy

James J. Hartman et al.

BIOPHYSICAL JOURNAL (2020)

Add to Collection

Review Cardiac & Cardiovascular Systems

Hypertrophic cardiomyopathy: the future of treatment

C. Vaughan Tuohy et al.

EUROPEAN JOURNAL OF HEART FAILURE (2020)

Add to Collection

Review Biochemistry & Molecular Biology

Direct Sarcomere Modulators Are Promising New Treatments for Cardiomyopathies

Osamu Tsukamoto

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

Add to Collection

Review Cardiac & Cardiovascular Systems

Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction Rationale and Design of GALACTIC-HF

John R. Teerlink et al.

JACC-HEART FAILURE (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial

Adriaan A. Voors et al.

EUROPEAN JOURNAL OF HEART FAILURE (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy

Carolyn Y. Ho et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial

Iacopo Olivotto et al.

LANCET (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

Steve R. Ommen et al.

CIRCULATION (2020)

Add to Collection

Review Physiology

Three perspectives on the molecular basis of hypercontractility caused by hypertrophic cardiomyopathy mutations

James A. Spudich

PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY (2019)

Add to Collection

Article Multidisciplinary Sciences

Proposed mechanism for the length dependence of the force developed in maximally activated muscles

Lorenzo Marcucci et al.

SCIENTIFIC REPORTS (2019)

Add to Collection

Article Medicine, General & Internal

Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy A Clinical Trial

Stephen B. Heitner et al.

ANNALS OF INTERNAL MEDICINE (2019)

Add to Collection

Article Clinical Neurology

A phase III trial of tirasemtiv as a potential treatment for amyotrophic lateral sclerosis

Jeremy M. Shefner et al.

AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION (2019)

Add to Collection

Article Chemistry, Medicinal

Discovery of Tirasemtiv, the First Direct Fast Skeletal Muscle Troponin Activator

Scott E. Collibee et al.

ACS MEDICINAL CHEMISTRY LETTERS (2018)

Add to Collection

Article Multidisciplinary Sciences

Deciphering the super relaxed state of human β-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers

Robert L. Anderson et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)

Add to Collection

Article Biochemistry & Molecular Biology

A small-molecule modulator of cardiac myosin acts on multiple stages of the myosin chemomechanical cycle

Raja F. Kawas et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2017)

Add to Collection

Article Multidisciplinary Sciences

Mechanistic and structural basis for activation of cardiac myosin force production by omecamtiv mecarbil

Vicente J. Planelles-Herrero et al.

NATURE COMMUNICATIONS (2017)

Add to Collection

Article Chemistry, Medicinal

Small Molecules in Development for the Treatment of Spinal Muscular Atrophy

Alyssa N. Calder et al.

JOURNAL OF MEDICINAL CHEMISTRY (2016)

Add to Collection

Article Cardiac & Cardiovascular Systems

Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure The ATOMIC-AHF Study

John R. Teerlink et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2016)

Add to Collection

Article Medicine, General & Internal

Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial

John R. Teerlink et al.

LANCET (2016)

Add to Collection

Article Multidisciplinary Sciences

A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice

Eric M. Green et al.

SCIENCE (2016)

Add to Collection

Article Cardiac & Cardiovascular Systems

High-Sensitivity Troponin: A Clinical Blood Biomarker for Staging Cardiomyopathy in Fabry Disease

Nora Seydelmann et al.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2016)

Add to Collection

Article Multidisciplinary Sciences

A Small Molecule Inhibitor of Sarcomere Contractility Acutely Relieves Left Ventricular Outflow Tract Obstruction in Feline Hypertrophic Cardiomyopathy

Joshua A. Stern et al.

PLOS ONE (2016)

Add to Collection

Review Cardiac & Cardiovascular Systems

Targets for therapy in sarcomeric cardiomyopathies

Jil C. Tardiff et al.

CARDIOVASCULAR RESEARCH (2015)

Add to Collection

Article Multidisciplinary Sciences

Fast Skeletal Muscle Troponin Activator tirasemtiv Increases Muscle Function and Performance in the B6SJL-SOD1G93A ALS Mouse Model

Darren T. Hwee et al.

PLOS ONE (2014)

Add to Collection

Article Cardiac & Cardiovascular Systems

B-Type Natriuretic Peptide and Survival in Hypertrophic Cardiomyopathy

Jeffrey B. Geske et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)

Add to Collection

Article Biochemistry & Molecular Biology

Activation of fast skeletal muscle troponin as a potential therapeutic approach for treating neuromuscular diseases

Alan J. Russell et al.

NATURE MEDICINE (2012)

Add to Collection

Article Medicine, General & Internal

Truncations of Titin Causing Dilated Cardiomyopathy

Daniel S. Herman et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

Add to Collection

Article Cardiac & Cardiovascular Systems

Improvement of Cardiac Function by a Cardiac Myosin Activator in Conscious Dogs With Systolic Heart Failure

You-Tang Shen et al.

CIRCULATION-HEART FAILURE (2010)

Add to Collection

Article Cardiac & Cardiovascular Systems

Mechanical and Energetic Consequences of HCM-Causing Mutations

Cecilia Ferrantini et al.

JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH (2009)

Add to Collection

Article Cardiac & Cardiovascular Systems

Hypertrophic cardiomyopathy - Distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy

P Richard et al.

CIRCULATION (2003)

Add to Collection

© Peeref 2019-2024. All rights reserved.